# Clinical Trial to Study the Efficacy and Safety of Fluorothiazinone (N.F. Gamaleya NRCEM) in Prophylaxis of Nosocomial Bacterial Infections With Participation of Patients on MV

> **NCT06135350** · PHASE2 · RECRUITING · sponsor: **Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation** · enrollment: 234 (estimated)

## Conditions studied

- Gram Negative Pneumonia
- Gram-Negative Bacterial Infections
- Bacteremia Caused by Gram-Negative Bacteria

## Interventions

- **DRUG:** Fluorothiazinone, tablets 300 mg at a dose of 2400 mg/day
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06135350
- **Lead sponsor:** Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-11-06
- **Primary completion:** 2025-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 234 (ESTIMATED)
- **Last updated:** 2025-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06135350

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06135350, "Clinical Trial to Study the Efficacy and Safety of Fluorothiazinone (N.F. Gamaleya NRCEM) in Prophylaxis of Nosocomial Bacterial Infections With Participation of Patients on MV". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06135350. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*